Key Takeaways
- • BMO Capital raised its price target on Ares Management (ARES) to $125 from $104, a 20% upward revision, while maintaining a Market Perform rating as of May 4, 2026.
- • The stock was trading at $123.18 as of the market close on May 13, 2026, placing it near BMO's revised target despite a year-to-date decline of 23.79%.
- • Ares Management trades with a consensus analyst rating of "Buy" and a mean price target of $146.47 according to FactSet, significantly above BMO's Market Perform stance, indicating divergence in institutional analyst views.
- • BMO's maintained Market Perform rating suggests cautious optimism relative to broader analyst sentiment, which leans overweight on the alternative asset manager.
Summary
The timing of BMO's adjustment comes as Ares Management traded near $123 per share in mid-May 2026, placing the stock marginally below the newly established target. The company's year-to-date performance has declined 23.79%, reflecting broader market pressures on asset managers during the period.
BMO's Market Perform rating contrasts notably with broader Street sentiment. According to FactSet data, Ares Management carries an average analyst rating of overweight with a mean price target of $146.47, approximately 17% above BMO's target. This disparity underscores meaningful disagreement among institutional research teams regarding the asset manager's near-term prospects. Other significant analyst positions on the stock have also shifted; Jefferies maintained coverage with a price target of $136, while prior guidance from TD Cowen and other houses suggests varied confidence levels across the investment banking and research community.
The analyst divergence reflects the complex positioning of alternative asset managers in the current market environment, where macroeconomic conditions, fee compression, and capital deployment cycles create uneven conviction across research desks. BMO's decision to raise its target while holding steady on its rating suggests incremental confidence in fundamentals without full alignment with the more bullish consensus view.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.